Dibucaine number
Dibucaine number-994
Dibucaine number
994
LAB994
MSO
Dibucaine inhibition
Assess the presence of homozygous or heterozygous “atypical” cholinesterase variant, in patients who have low result of serum or plasma cholinesterase assay, and may be at risk of apnea when given succinylcholine muscle relaxant.
No single simple test currently exists that can detect all enzyme variants.
Do not collect within 24 hours of administration of muscle relaxant
Serum
0.5 mL
0.2 mL
Immediately following collection, thoroughly mix sample by gently inverting 5 times
- Allow sample to clot for a minimum of 30 minutes
- Spin within two (2) hours of sample collection
- Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum
EDTA plasma
Lavender:
Immediatley following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting
Red:
- Allow sample to clot
- Spin
- Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum, within two (2) hours of sample collection
Lavender:
- Spin
- Transfer plasma to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as EDTA plasma, within two (2) hours of sample collection
Ambient (preferred) - 14 days
Refrigerated - 14 days
Frozen - 14 days
Freeze/thaw cycles - stable x3
- Plasma or serum not separated from cells
- Frozen whole blood received
- Hemolysis
LabCorp Burlington (081513): R-NX
Su - Fr
3 - 5 days
Cholinesterase by spectrophotometry (Ellman) with dibucaine inhibition
Normal: 70% - 90% inhibition
Heterozygotes: 30% - 70% inhibition
Homozygotes: 0% - 30% inhibition
Heterozygotes: 30% - 70% inhibition
Homozygotes: 0% - 30% inhibition
82638
Result 39354-6
05/30/2019
06/13/2023
06/01/2023